National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK‑positive tumour mutations should also have received targeted therapy before receiving atezolizumab.

NCPE Rapid Review Process Complete
Rapid Review  Comissioned 08/08/2017
Rapid Review Completed 09/10/2017
Outcome Full pharmacoeconomic assessment recommended